Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to find out if 4-hour continuous infusion of parenteral
P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI)
immediately and effectively suppresses platelet activity in comatose survivors of
out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard
care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via
nasogastric or orogastric tube and the other half the standard care with additional cangrelor
infusion at the start of the PCI.